Legal & General Group
XERS icon

Legal & General Group’s Xeris Biopharma Holdings XERS Stock Holding History

Legal & General Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9M Buy
2,012,792
+104,503
+5% +$667K ﹤0.01% 975
2026
Q1 		$11.1M Buy
1,908,289
+512,024
+37% +$3.39M ﹤0.01% 1071
2025
Q4 		$11M Buy
1,396,265
+38,838
+3% +$306K ﹤0.01% 1117
2025
Q3 		$11M Sell
1,357,427
-446,776
-25% -$2.97M ﹤0.01% 1157
2025
Q2 		$8.43M Buy
1,804,203
+392,589
+28% +$1.8M ﹤0.01% 1279
2025
Q1 		$7.75M Buy
1,411,614
+1,181,147
+513% +$4.77M ﹤0.01% 1282
2024
Q4 		$781K Buy
230,467
+19,624
+9% +$63.1K ﹤0.01% 2320
2024
Q3 		$601K Buy
210,843
+195,973
+1,318% +$503K ﹤0.01% 2399
2024
Q2 		$33.5K Buy
14,870
+323
+2% +$651 ﹤0.01% 2860
2024
Q1 		$32.1K Hold
14,547
– – ﹤0.01% 2842
2023
Q4 		$34.2K Sell
14,547
-788
-5% -$1.45K ﹤0.01% 2867
2023
Q3 		$28.5K Sell
15,335
-1,323
-8% -$3.03K ﹤0.01% 2933
2023
Q2 		$43.6K Buy
16,658
+84
+0.5% +$214 ﹤0.01% 2890
2023
Q1 		$26.9K Hold
16,574
– – ﹤0.01% 2988
2022
Q4 		$22K Hold
16,574
– – ﹤0.01% 3131
2022
Q3 		$26K Sell
16,574
-8,959
-35% -$14.8K ﹤0.01% 3141
2022
Q2 		$39K Buy
+25,533
New +$53.9K ﹤0.01% 3047
2021
Q2 		– Sell
-5,109
Closed -$23K – 3664
2021
Q1 		$23K Sell
5,109
-22,799
-82% -$123K ﹤0.01% 3080
2020
Q4 		$138K Buy
27,908
+22,500
+416% +$113K ﹤0.01% 2501
2020
Q3 		$32K Sell
5,408
-1,050
-16% -$4.2K ﹤0.01% 2829
2020
Q2 		$17K Buy
6,458
+324
+5% +$1.13K ﹤0.01% 3140
2020
Q1 		$13K Buy
6,134
+709
+13% +$3.05K ﹤0.01% 3097
2019
Q4 		$38K Buy
5,425
+964
+22% +$7.96K ﹤0.01% 2931
2019
Q3 		$44K Hold
4,461
– – ﹤0.01% 2791
2019
Q2 		$48K Buy
4,461
+974
+28% +$10.2K ﹤0.01% 2794
2019
Q1 		$35K Buy
3,487
+2,482
+247% +$31.8K ﹤0.01% 2858
2018
Q4 		$17K Hold
1,005
– – ﹤0.01% 3149
2018
Q3 		$18K Buy
+1,005
New +$21.8K ﹤0.01% 3238

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group's XERS Position: Q2 2026 in Review

Legal & General Group increased its Xeris Biopharma Holdings (XERS) stake by 5.5% in Q2 2026, buying an estimated $667K and bringing the position to 2,012,792 shares worth $15.9M. The position accounts for ﹤0.01% of the portfolio, ranked #975.

Legal & General Group first reported a position in XERS in Q3 2018 and has held it in 28 quarters since. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Legal & General Group held 2,012,792 shares of Xeris Biopharma Holdings worth $15.9M as of Q2 2026.
  • Legal & General Group bought 104,503 Xeris Biopharma Holdings shares in Q2 2026, an estimated $667K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #975 holding.
  • Legal & General Group first reported a position in Xeris Biopharma Holdings in Q3 2018 and has held it in 28 quarters since.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.